Metastasis-associated mutations in clear cell renal cell carcinoma. This is an ASCO Meeting Abstract from the 2016 Genitourinary Cancers Symposium. This abstract does not include a full text component ...
Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
First described in 1985, chromophobe RCC accounts for approximately 5% of renal tumors.15 This RCC subtype has a better prognosis than either clear cell or papillary RCC, but it is worth noting that ...
RCC contributes to approximately 4% of adult malignancies. To date, four major inherited RCC syndromes have been identified. This PDQ summary provides a reference on the genetics of RCC for clinicians ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results